Innate Signatures of Immune Mediated Resolution and Persistence of Hepatitis C Virus Infections

  • Robert E. Lanford


Hepatitis C Virus infections have a high propensity to induce lifelong persistent infections. A number of host and environmental variables have been shown to impact the rate of persistent infection and the outcome of interferon (IFN)-based therapies. This review briefly highlights a few of the relevant observations that have been made with regard to viral clearance. HCV infection induces a highly elevated interferon stimulated gene (ISG) response in the liver during both acute and chronic infections. The role of this response in containing the spread of the virus in the liver and in mounting an effective adaptive immune response is poorly understood. The fact that an elevated hepatic ISG response during chronic infection negatively correlates with the outcome of IFN therapy is counter-intuitive and remains to be explained satisfactorily. The failure of the T cell response to clear virus appears to reside in a deficiency in the CD4 T cell help leading to anergic CD8 T cells, which may also be related to whether the innate response properly orchestrates the adaptive T cell response early in infection. The importance of the innate response in the outcome of infection is illustrated by recent genome wide association studies revealing a remarkable correlation between genetic polymorphisms in IL28B (IFNλ3) and clearance of infected cells whether during acute infection or IFN therapy, yet the mechanisms by which IFNλ3 and other innate effectors influence HCV infection are currently poorly understood.


Chimpanzee Chronic infection HCV Hepatitis C virus Hepatocyte IL28 Innate immune response Interferon Interferon lambda ISG Liver Microarray Persistent infection 


  1. Bassett SE, Guerra B, Brasky K et al Protective immune response to hepatitis C virus in chimpa­nzees rechallenged following clearance of primary infection (2001) Hepatology 33: 1479–1487.PubMedCrossRefGoogle Scholar
  2. Bigger CB, Brasky KM, Lanford RE DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection (2001) J Virol 75: 7059–7066.PubMedCrossRefGoogle Scholar
  3. Bigger CB, Guerra B, Brasky KM et al Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees (2004) J Virol 78: 13779–13792.PubMedCrossRefGoogle Scholar
  4. Bowen DG, Walker CM Adaptive immune responses in acute and chronic hepatitis C virus infection (2005) Nature 436: 946–952.PubMedCrossRefGoogle Scholar
  5. Bukh J, Thimme R, Meunier JC et al Previously infected chimpanzees are not consistently ­protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain (2008) J Virol 82: 8183–8195.PubMedCrossRefGoogle Scholar
  6. Butera D, Marukian S, Iwamaye AE et al Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C (2005) Blood 106: 1175–1182.PubMedCrossRefGoogle Scholar
  7. Chen LM, Borozan I, Feld J et al Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection (2005) Gastroenterology 128: 1437–1444.PubMedCrossRefGoogle Scholar
  8. Cooper S, Erickson AL, Adams EJ et al Analysis of a successful immune response against hepatitis C virus (1999) Immunity 10: 439–449.PubMedCrossRefGoogle Scholar
  9. Cox AL, Mosbruger T, Lauer GM et al Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C (2005a) Hepatology 42: 104–112.PubMedCrossRefGoogle Scholar
  10. Cox AL, Mosbruger T, Mao Q et al Cellular immune selection with hepatitis C virus persistence in humans (2005b) J Exp Med 201: 1741–1752.PubMedCrossRefGoogle Scholar
  11. Day CL, Kaufmann DE, Kiepiela P et al PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression (2006) Nature 443: 350–354.PubMedCrossRefGoogle Scholar
  12. Diago M, Castellano G, Garcia-Samaniego J et al Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C (2006) Gut 55: 374–379.PubMedCrossRefGoogle Scholar
  13. Diepolder HM, Zachoval R, Hoffmann RM et al Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection (1995) Lancet 346: 1006–1007.PubMedCrossRefGoogle Scholar
  14. Enomoto N, Sakuma I, Asahina Y et al Interferon sensitivity determining sequence of the hepatitis C virus genome (1996) Hepatology 24: 460–461.Google Scholar
  15. Feld JJ, Nanda S, Huang Y et al Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response (2007) Hepatology 46: 1548–1563.PubMedCrossRefGoogle Scholar
  16. Flisiak R, Feinman SV, Jablkowski M et al The cyclophilin inhibitor debio 025 combined with PEG IFN alpha 2a significantly reduces viral load in treatment-naive Hepatitis C patients (2009) Hepatology 49: 1460–1468.PubMedCrossRefGoogle Scholar
  17. Foy E, Li K, Sumpter R et al Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling (2005) Proc Natl Acad Sci U S A 102: 2986–2991.PubMedCrossRefGoogle Scholar
  18. Foy E, Li K, Wang CF et al Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease (2003) Science 300: 1145–1148.PubMedCrossRefGoogle Scholar
  19. Fuller MJ, Shoukry NH, Gushima T et al Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection (2010) Hepatology 51: 378–387.PubMedCrossRefGoogle Scholar
  20. Gale M, Blakely CM, Kwieciszewski B et al Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation (1998) Mol Cell Biol 18: 5208–5218.PubMedGoogle Scholar
  21. Ge D, Fellay J, Thompson AJ et al Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance (2009) Nature 461: 399–401.PubMedCrossRefGoogle Scholar
  22. Grakoui A, Shoukry NH, Woollard DJ et al HCV persistence and immune evasion in the absence of memory T cell help (2003) Science 302: 659–662.PubMedCrossRefGoogle Scholar
  23. Grakoui A, John Wherry E, Hanson HL et al Turning on the off switch: Regulation of anti-viral T cell responses in the liver by the PD-1/PD-L1 pathway (2006) J Hepatol 45: 468–472.PubMedCrossRefGoogle Scholar
  24. Helbig KJ, Ruszkiewicz A, Lanford RE et al Differential expression of the CXCR3 ligands in chronic hepatitis C virus (HCV) infection and their modulation by HCV in vitro (2009) J Virol 83: 836–846.PubMedCrossRefGoogle Scholar
  25. Huang Y, Feld JJ, Sapp RK et al Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C (2007) Gastroenterology 132: 733–744.PubMedCrossRefGoogle Scholar
  26. Kawai T, Takahashi K, Sato S et al IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction (2005) Nat Immunol 6: 981–988.PubMedCrossRefGoogle Scholar
  27. Kenny-Walsh E, Irish HRG Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin (1999) N Engl J Med 340: 1228–1233.PubMedCrossRefGoogle Scholar
  28. Khakoo SI, Thio CL, Martin MP et al HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection (2004) Science 305: 872–874.PubMedCrossRefGoogle Scholar
  29. Lagging M, Romero A, Westin J et al IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients With HCV genotype 1 infection (2006) Hepatology 44: 1617–1625.PubMedCrossRefGoogle Scholar
  30. Lanford RE The Chimpanzee model of HCV (2006). In: R. F. Schinazi, E. R. Schiff (Eds.), Framing The Knowledge of Viral Hepatitis. pp. 197–218.Google Scholar
  31. Lanford RE, Guerra B, Bigger CB et al Lack of response to exogenous interferon-alpha in the liver of HCV chronically infected chimpanzees (2007) Hepatology 46: 999–1008.PubMedCrossRefGoogle Scholar
  32. Lanford RE, Guerra B, Chavez D et al Cross-genotype immunity to hepatitis C virus (2004) J Virol 78: 1575–1581.PubMedCrossRefGoogle Scholar
  33. Lanford RE, Guerra B, Lee H et al Genomic response to interferon-alpha in chimpanzees: Implications of rapid downregulation for hepatitis C kinetics (2006) Hepatology 43: 961–972.PubMedCrossRefGoogle Scholar
  34. Lanford RE, Hildebrandt-Eriksen ES, Petri A et al Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection (2010) Science 327: 198–201.PubMedCrossRefGoogle Scholar
  35. Lechner F, Wong DK, Dunbar PR et al Analysis of successful immune responses in persons infected with hepatitis C virus (2000) J Exp Med 191: 1499–1512.PubMedCrossRefGoogle Scholar
  36. Li K, Foy E, Ferreon JC et al Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF (2005) Proc Natl Acad Sci USA 102: 2992–2997.PubMedCrossRefGoogle Scholar
  37. Liang Y, Shilagard T, Xiao SY et al Visualizing hepatitis C virus infections in human liver by two-photon microscopy (2009) Gastroenterology 137: 1448–1458.PubMedCrossRefGoogle Scholar
  38. Lin W, Kim SS, Yeung E et al Hepatitis C Virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain (2006) J Virol 80: 9226–9235.PubMedCrossRefGoogle Scholar
  39. Major ME, Mihalik K, Puig M et al Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge (2002) J Virol 76: 6586–6595.PubMedCrossRefGoogle Scholar
  40. Marcello T, Grakoui A, Barba-Spaeth G et al Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics (2006) Gastroenterology 131: 1887–1898.PubMedCrossRefGoogle Scholar
  41. Mehta SH, Cox A, Hoover DR et al Protection against persistence of hepatitis C (2002) Lancet 359: 1478–1483.PubMedCrossRefGoogle Scholar
  42. Meylan E, Curran J, Hofmann K et al Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus (2005) Nature 437: 1167–1172.PubMedCrossRefGoogle Scholar
  43. Miller DM, Klucher KM, Freeman JA et al Interferon lambda as a potential new therapeutic for hepatitis C (2009) Ann N Y Acad Sci 1182: 80–87.PubMedCrossRefGoogle Scholar
  44. Nakamoto N, Kaplan DE, Coleclough J et al Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization (2008) Gastroenterology 134: 1927–1937, 1937.e 1–2.Google Scholar
  45. Nascimbeni M, Mizukoshi E, Bosmann M et al Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees (2003) J Virol 77: 4781–4793.PubMedCrossRefGoogle Scholar
  46. Neumann AU, Lam NP, Dahari H et al Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy (1998) Science 282: 103–107.PubMedCrossRefGoogle Scholar
  47. Osburn WO, Fisher BE, Dowd KA et al Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection (2010) Gastroenterology 138: 315–324.PubMedCrossRefGoogle Scholar
  48. Polyak SJ, Khabar KSA, Paschal DM et al Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response (2001) J Virol 75: 6095–6106.PubMedCrossRefGoogle Scholar
  49. Prince AM, Brotman B, Lee DH et al Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model (2005) J Infect Dis 192: 1701–1709.PubMedCrossRefGoogle Scholar
  50. Radziewicz H, Ibegbu CC, Fernandez ML et al Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression (2007) J Virol 81: 2545–2553.PubMedCrossRefGoogle Scholar
  51. Rehermann B, Nascimbeni M Immunology of hepatitis B virus and hepatitis C virus infection (2005) Nat Rev Immunol 5: 215–229.PubMedCrossRefGoogle Scholar
  52. Robek MD, Boyd BS, Chisari FV Lambda interferon inhibits hepatitis B and C virus replication (2005) J Virol 79: 3851–3854.PubMedCrossRefGoogle Scholar
  53. Romero AI, Lagging M, Westin J et al Interferon (IFN)-[gamma]-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-[alpha]2a and ribavirin for chronic hepatitis C virus infection (2006) J Infect Dis 194: 895–903.PubMedCrossRefGoogle Scholar
  54. Sarasin-Filipowicz M, Oakeley EJ, Duong FH et al Interferon signaling and treatment outcome in chronic hepatitis C (2008) Proc Natl Acad Sci U S A 105: 7034–7039.PubMedCrossRefGoogle Scholar
  55. Seth RB, Sun L, Ea CK et al Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kB and IRF3 (2005) Cell 122: 669–682.PubMedCrossRefGoogle Scholar
  56. Shimakami T, Lanford RE, Lemon SM Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities (2009) Curr Opin Pharmacol 9: 537–544.PubMedCrossRefGoogle Scholar
  57. Shoukry NH, Grakoui A, Houghton M et al Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection (2003) J Exp Med 197: 1645–1655.PubMedCrossRefGoogle Scholar
  58. Su AI, Pezacki JP, Wodicka L et al Genomic analysis of the host reponse to hepatitis C virus infection (2002) Proc Natl Acad Sci U S A 99: 15669–15674.PubMedCrossRefGoogle Scholar
  59. Suppiah V, Moldovan M, Ahlenstiel G et al IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy (2009) Nat Genet 41: 1100–1104.PubMedCrossRefGoogle Scholar
  60. Tanaka Y, Nishida N, Sugiyama M et al Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C (2009) Nat Genet 41: 1105–1109.PubMedCrossRefGoogle Scholar
  61. Thimme R, Oldach D, Chang KM et al Determinants of viral clearance and persistence during acute hepatitis C virus infection (2001) J Exp Med 194: 1395–1406.PubMedCrossRefGoogle Scholar
  62. Thomas DL, Astemborski J, Rai RM et al The natural history of hepatitis C virus infection - Host, viral, and environmental factors (2000) JAMA 284: 450–456.PubMedCrossRefGoogle Scholar
  63. Thomas DL, Thio CL, Martin MP et al Genetic variation in IL28B and spontaneous clearance of hepatitis C virus (2009) Nature 461: 798–801.PubMedCrossRefGoogle Scholar
  64. Urbani S, Amadei B, Tola D et al PD-1 expression in acute hepatitis C is associated with HCV-specific CD8 exhaustion (2006) J Virol 80: 11398–11403.PubMedCrossRefGoogle Scholar
  65. Weiner A, Erickson AL, Kansopon J et al Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant (1995) Proc Natl Acad Sci U S A 92: 2755–2759.PubMedCrossRefGoogle Scholar
  66. Xu LG, Wang YY, Han KJ et al VISA is an adapter protein required for virus-triggered IFN-beta signaling (2005) Mol Cell 19: 727–740.PubMedCrossRefGoogle Scholar
  67. Zhu H, Butera M, Nelson DR et al Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication (2005) Virol J 2: 80.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Virology and ImmunologySouthwest Foundation for Biomedical Research and Southwest National Primate Research CenterSan AntonioUSA

Personalised recommendations